A method of molecular imaging that pinpoints hormonally active tissues in the body could change the course of treatment for a remarkable number of neuroendocrine cancer patients, say researchers at the Society of Nuclear Medicine's 59th Annual Meeting.

Results of the study indicated that PET/CT and Ga-68 DOTATATE was highly sensitive and specific for assessing neuroendocrine tumors and changed thecourse of treatment for a large number of patients. Prior to imaging, more than half of the

On April 10, 2012 a 42 center worldwide trial of PRRT using LU177 was announced with sites in the US and Europe.

Detailed Description:

A multicenter, stratified, open, randomized, comparator-controlled, parallel-group phase III study. In this study, treatment with 177Lu-DOTA0-Tyr3-Octreotate plus best supportive care (30 mg Octreotide LAR) will be compared to treatment with high dose (60 mg) Octreotide LAR in patients with inoperable, somatostatin receptor positive, histologically proven

Dr. Richard P. Baum, was honored by the Society of Nuclear Medicine, India in Chennai on December 8, 2011 and received the AGASTHIAR AWARD for his "Life Time Contribution to The Field of Nuclear Medicine". Prof. Baum was also appointed "Visiting Professor" of the FM Medical University (Tandu Hospital) in Xi'an, Shaanxi, China where he initiated a project on Ga-68 imaging and PRRNT which will be the first place in China where THERANOSTICS will be performed. The initial effort for this

Steve Jobs lost his battle with NETs in October 2011, many sites have chronicled his medical care and the various medical treatments he pursued including PRRT.  For a detailed look at his medical history and treatment - click here to view the article from Science-Based Medicine.
Aug 24, 2011 - Steve Jobs - Apple's CEO resigned today saying he "could no longer meet my duties and expectations as Apple's CEO'.  Mr. Jobs has been battling pancreatic neuroendocrine cancer since 2004 and most recently had a liver transplant in 2009.  For more coverage of Mr. Jobs' resignation click here.

Bad Berka, Germany

With over 350 participants from 30 countries representing the 5 continents, the 1st World Congress on GA68 and PRRNT marks a historical moment in the history of imaging and therapy for individuals with Neuroendocrine tumors as well as other diseases that can be imaged with GA68.

Please enjoy the photo gallery below. Viewing on an iPhone, iPad or other device that does not support flash? click here.

The final program has been announced for the 1st World Congress on Ga-68 and Peptide Receptor Radionuclide Therapy to be held June 23rd-26th, 2011 in Bad Berka, Germany.

Please click here to download the agenda.

Response, Survival, and Long-Term Toxicity After Therapy With the Radiolabeled Somatostatin Analogue [90Y-DOTA]-TOC in Metastasized Neuroendocrine Cancers.

Published in Journal of Clinical Oncology,  2011 May 9;[Epub Ahead of Print], A Imhof, P Brunner, N Marincek, M Briel, C Schindler, H Rasch, HR Mäcke, C Rochlitz, J Müller-Brand, MA Walter

To read a review of the JCO article please visit OncologyStat (free registration is required to read the summary of findings.)

1st World Congress on Ga-68 and Peptide Receptor Radionuclide Therapy

THERANOSTICS – on the Way to Personalized Medicine

Since 1997, when he first used the radiolabeled peptide Y-90 DOTATOC (a somatostatin anlogue) to treat a 15-year-old boy with a rare neuroendocrine tumor, called paraganglioma, and saw the boy go from being wheelchair-bound and in terrible pain to a young man of 20 who was walking and playing soccer, Prof. Dr. med. Richard P. Baum has been passionate about Peptide

certificate_ENETSJanuary 2011 - European Neuroendocrine Tumor Society has certified Zentralklink Bad Berka as an ENETS Centers of Excellence.  The certification states that center meets all quality standards defined by ENETS for interdisciplinary diagnostics, medical treatment and aftercare of patients with neuroendocrine tumors.  Click here to download a copy of the certificate.